Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors

Talimogene laherparepvec is a genetically modified herpes simplex virus type 1–based oncolytic immunotherapy for the local treatment of unresectable subcutaneous and nodal tumors in patients with melanoma recurrent after initial surgery. We report on two patients with melanoma who, after progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesney, Jason, Imbert-Fernandez, Yoannis, Telang, Sucheta, Baum, Mary, Ranjan, Smita, Fraig, Mostafa, Batty, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929488/
https://www.ncbi.nlm.nih.gov/pubmed/29561296
http://dx.doi.org/10.1097/CMR.0000000000000444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929488/
https://www.ncbi.nlm.nih.gov/pubmed/29561296
http://dx.doi.org/10.1097/CMR.0000000000000444

Ejemplares similares